MedTrace Logo

Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)

NCT00085332 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-01-13

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma (cancer).

Conditions

Interventions

DRUG

docetaxel

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Agustin Garcia, MD · Premiere Oncology

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-12-31

Countries

  • United States
  • Australia
  • Canada
  • Japan
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00085332 on ClinicalTrials.gov